Progesterone - Merck/AbbVie

Drug Profile

Progesterone - Merck/AbbVie

Alternative Names: Prometrium

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Amenorrhoea; Menopausal syndrome

Most Recent Events

  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 22 Jul 2013 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top